Detalles de la búsqueda
1.
A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer.
Ann Oncol
; 19(10): 1691-7, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18504252
2.
Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
J Clin Oncol
; 12(2): 353-9, 1994 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-8113843
3.
Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party.
J Clin Oncol
; 11(10): 1858-65, 1993 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-8410110
4.
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
J Clin Oncol
; 16(4): 1388-96, 1998 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-9552042
5.
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.
J Clin Oncol
; 14(8): 2337-44, 1996 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-8708726
6.
A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
Lung Cancer
; 50(1): 75-82, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16005104
7.
A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.
Eur J Cancer
; 35(9): 1314-9, 1999 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-10658520
8.
Induction chemotherapy with ifosfamide, etoposide, and anthracycline for small cell lung cancer: experience of the European Lung Cancer Working Party.
Semin Oncol
; 22(1 Suppl 2): 18-22, 1995 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-7846537
9.
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5 fluorouracile: a regimen associated with major toxicity in patients with advanced non-small cell lung cancer.
Lung Cancer
; 11(5-6): 373-84, 1994 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-7704494
10.
Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC).
Lung Cancer
; 16(1): 21-33, 1996 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-9017582
11.
Evaluation of the TN sub-staging in patients with initially unresectable stage III non-small cell lung cancer treated by induction chemotherapy. The European Lung Cancer Working Party.
Lung Cancer
; 22(3): 201-13, 1998 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-10048473
12.
[Small cell bronchial cancer. Comparison of results of weekly polychemotherapy using multiple drugs with standard chemotherapy. European Lung Cancer Working Party]. / Cancer bronchique à petites cellules. Comparaison des résultats d'une polychimiothérapie hebdomadaire avec de multiples médicaments avec une chimiothérapie standard. European Lung Cancer Working Party.
Rev Mal Respir
; 11(3): 257-61, 1994.
Artículo
en Francés
| MEDLINE | ID: mdl-8041988
13.
[Prognostic factors in advanced stage non-small cell bronchial cancer: experiences of the European Lung Cancer Working Party]. / Facteurs pronostiques des cancers bronchiques non à petites cellules au stade avancé: expérience de l'European Lung Cancer Working Party.
Rev Mal Respir
; 14(6): 445-9, 1997 Dec.
Artículo
en Francés
| MEDLINE | ID: mdl-9496602
14.
Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): a phase II randomised study by the European Lung Cancer Working Party.
Lung Cancer
; 77(3): 605-10, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22704426
15.
Chemotherapy improves low performance status lung cancer patients.
Eur Respir J
; 30(6): 1186-92, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17690124
16.
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
Br J Cancer
; 96(11): 1644-9, 2007 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-17473825
17.
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.
Ann Oncol
; 18(6): 1037-42, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17404152
18.
A four-drug combination chemotherapy with cisplatin, mitomycin, vindesine and 5-fluorouracil. A regimen associated with major toxicity in patients with advanced non-small lung cancer. European Lung Cancer Working Party.
Ann Oncol
; 5(7): 641-3, 1994 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-7993841
19.
Monoclonal immunoradiometric assay and polyclonal radioimmunoassay compared for measuring neuron-specific enolase in patients with lung cancer.
Clin Chem
; 38(5): 748-51, 1992 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-1316245
20.
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics.
Br J Cancer
; 85(10): 1444-51, 2001 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-11720426